Skip to main content
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc — Investor Relations & Filings

Ticker · CURX ISIN · US23126K1060 US Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US CURX

About Curanex Pharmaceuticals Inc

https://www.curanexpharma.com/

Curanex Pharmaceuticals Inc. is a developmental-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative botanical drugs. The company's primary efforts are directed towards creating treatments for patients suffering from inflammatory diseases, with a particular emphasis on developing therapies for moderate to severe ulcerative colitis. Its research platform has also validated effects in animal models for other inflammatory conditions, including atopic dermatitis and COVID-19.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 85% confidence The document is a Form 8-K current report under the Securities Exchange Act, specifically an Item 7.01 Regulation FD Disclosure announcing the issuance of a press release. It contains no actual financial statements or managerial changes, nor is it an earnings release, proxy statement, or other specialized report. As a standard SEC regulatory announcement that does not fit into a more specific category, it falls under the generic Regulatory Filings category (RNS).
2026-05-14 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
Regulatory Filings
2026-05-07 English
8-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 2, 2026, by Curanex Pharmaceuticals Inc. It includes a press release about expanding the drug development pipeline, specifically mentioning a new core indication for cancer cachexia. The document explicitly states it is a Current Report on Form 8-K, which is used for unscheduled material events or corporate changes that shareholders should know about. The content is a disclosure of a press release and does not contain financial statements or detailed financial data. The length is 4274 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories such as earnings releases or annual reports.
2026-04-02 English
10-K - Curanex Pharmaceuticals Inc (0002025942) (Filer)
Annual Report FY 2025
2026-03-30 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the resignation of the Chief Financial Officer and Treasurer, Haiyan Yang, and the appointment of a new CFO, Wanjun Zhang, including his background and the terms of his consulting agreement. This fits the description of announcements related to changes in the company's board of directors or senior management. There are no financial statements or detailed financial data presented, so it is not an Annual Report or Interim Report. The document is not a proxy solicitation, earnings release, or any other category. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is sufficient and contains substantive information about management changes, supporting a high confidence score.
2026-01-05 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.